Effects of Atorvastatin on Atherosclerosis and Atherogenesis in Systemic Lupus Erythematosus: A Pilot Study
Table 4
Adjusted mean changes of measured variables (95% confidence interval).
Variable
Placebo ()
Atorvastatin ()
Difference
OxLDLβ 2GPI u/mL
0.29 (−0.06 to 0.64)
−0.62 (−0.99 to −0.26)
−0.92 (−1.45 to −0.39)
12.97
0.002
CRP µg/mL
−1.28 (−2.45 to −0.11)
−2.89 (−4.11 to −1.66)
−1.61 (−3.41 to 0.19)
3.47
0.077
SAA µg/mL
−10.28 (−12.26 to −8.30)
−8.53 (−10.60 to −6.46)
1.75 (−1.28 to 4.79)
1.45
0.243
µM
−0.62 (−8.00 to 6.76)
−5.58 (−13.30 to 2.14)
−4.96 (−16.27 to 6.35)
0.84
0.371
µM#
−0.09 (−0.34 to 0.15)4
0.10 (−0.14 to 0.35)
0.20 (−0.57 to 0.18)
1.20
0.288
NT nM#
0.95 (0.15 to 1.75)
0.65 (−0.18 to 1.49)
−0.30 (−0.93 to 1.52)
0.26
0.619
TG mmol/L
−0.02 (−0.35 to 0.30)1
−0.33 (−0.34 to −0.03)2
−0.31 (−0.77 to 0.15)
2.09
0.170
CHO mmol/L
0.38 (−0.19 to 0.96)1
−1.39 (−1.86 to −0.91)
−1.77 (−2.61 to −0.92)
19.64
<0.001
LDL mmol/L
0.42 (0.07 to 0.78)2
−1.13 (−1.47 to −0.79)3
−1.55 (−2.07 to −1.03)
40.23
<0.001
HDL mmol/L
0.04 (−0.10 to 0.17)4
−0.01 (−0.14 to 0.13)
−0.04 (−0.26 to 0.17)
0.18
0.677
PON U/L
1.15 (−14.48 to 16.79)4
3.40 (−12.24 to 19.03)
2.24 (−24.10 to 28.59)
0.03
0.860
PON/HDL
−7.19 (−17.45 to 3.07)4
13.04 (2.78 to 23.30)
20.23 (4.81 to 35.64)
7.54
0.013
PDN mg/day
1.00 (−1.07 to 3.07)2
−1.04 (−2.91 to 0.82)4
−2.04 (−5.00 to 0.91)
2.13
0.163
IMT CC mm
−0.002 (−0.006 to 0.002)
0.003 (−0.002 to 0.007)2
0.005 (−0.011 to 0.001)
2.59
0.125
oxLDLβ 2GPI: oxidised low density lipoprotein beta-2-glycoprotein-1 complex; CRP: C-reactive protein; SAA: serum amyloid A; : nitrate; : nitrite; NT: nitrotyrosine; TG: triglycerides; CHO: total cholesterol; LDL: low density lipoprotein; HDL: high density lipoprotein; PON: paraoxonase; PDN: prednisolone. Data adjusted for baseline age and disease duration. (1, 2, 3, 4; #dependent variable = difference between ln (follow-up + 1) and ln (baseline + 1), covariate = ln (baseline + 1).
We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.
